Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $66.75.
A number of research firms recently commented on ARCT. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a report on Monday, January 13th.
Get Our Latest Analysis on Arcturus Therapeutics
Institutional Investors Weigh In On Arcturus Therapeutics
Arcturus Therapeutics Price Performance
Arcturus Therapeutics stock opened at $16.79 on Friday. Arcturus Therapeutics has a 52-week low of $14.30 and a 52-week high of $45.00. The stock has a fifty day moving average price of $17.46 and a two-hundred day moving average price of $19.85. The firm has a market capitalization of $454.84 million, a P/E ratio of -7.56 and a beta of 2.63.
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same period last year, the firm posted ($0.61) EPS. On average, equities research analysts predict that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Read More
- Five stocks we like better than Arcturus Therapeutics
- What does consumer price index measure?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.